
Releases
ADMA Biologics Faces Securities Fraud Lawsuit After Channel Stuffing Claims
Investors who purchased ADMA Biologics securities between August 9, 2024, and March 25, 2026, are facing a class action lawsuit following allegations of revenue manipulation and undisclosed transactions. The legal action centers on claims that the company inflated its financial performance through aggressive distribution tactics and inadequate internal controls.
























